Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Actinogen Suspended As It Analyses XanaMIA Alzheimer’s Trial Data

Actinogen Medical has requested a voluntary suspension while it completes further analysis of additional data received for its XanaMIA phase 2b/3 Alzheimer’s trial, ahead of releasing topline results. The suspension is requested to remain in place until the results announcement or the start of trading on Thursday.

Source announcements: 2026-11-17 10:33 to 2026-11-17 10:33 Sydney time
Story updated 2026-11-17 10:35 Sydney time
SourcesSuspension from Quotation
Comments